CA2734802C
(en)
*
|
2008-08-22 |
2016-05-31 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
ES2561216T3
(es)
|
2009-05-13 |
2016-02-25 |
The University Of North Carolina At Chapel Hill |
Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
AU2011240735B2
(en)
*
|
2010-04-13 |
2015-01-29 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (CDK4/6) inhibitor and an mTOR inhibitor for treating cancer
|
CN106198656B
(zh)
|
2010-08-18 |
2018-12-11 |
生命科技股份有限公司 |
用于电化学检测装置的微孔的化学涂层
|
BR112013010018B1
(pt)
|
2010-10-25 |
2020-11-10 |
G1 Therapeutics, Inc. |
compostos inibidores de quinase dependente de ciclina e composição farmacêutica
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
US20120115878A1
(en)
*
|
2010-11-10 |
2012-05-10 |
John Vincent Calienni |
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
|
JP2013545758A
(ja)
|
2010-11-17 |
2013-12-26 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
増殖性キナーゼcdk4及びcdk6の阻害による虚血からの腎組織の保護
|
SG191844A1
(en)
*
|
2011-01-04 |
2013-08-30 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
AU2012279117A1
(en)
*
|
2011-07-01 |
2014-01-09 |
Novartis Ag |
Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
|
KR20140040769A
(ko)
*
|
2011-07-01 |
2014-04-03 |
노파르티스 아게 |
조합 요법
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
AU2013239816B2
(en)
*
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
WO2013163239A1
(en)
*
|
2012-04-26 |
2013-10-31 |
Francis Xavier Tavares |
Synthesis of lactams
|
EP2867225B1
(en)
|
2012-06-28 |
2017-08-09 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
EP2867227B1
(en)
|
2012-06-28 |
2018-11-21 |
Novartis AG |
Complement pathway modulators and uses thereof
|
US9815819B2
(en)
|
2012-06-28 |
2017-11-14 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
ES2644700T3
(es)
|
2012-06-28 |
2017-11-30 |
Novartis Ag |
Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
|
US9464081B2
(en)
|
2012-06-28 |
2016-10-11 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
EP2872503B1
(en)
|
2012-07-12 |
2018-06-20 |
Novartis AG |
Complement pathway modulators and uses thereof
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
EP4119676A1
(en)
|
2012-08-03 |
2023-01-18 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
EP3251673A1
(en)
|
2012-12-13 |
2017-12-06 |
IP Gesellschaft für Management mbH |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
US9867825B2
(en)
*
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
EP2959013A2
(en)
|
2013-02-25 |
2015-12-30 |
Novartis AG |
Novel androgen receptor mutation
|
BR112015023013A2
(pt)
|
2013-03-13 |
2017-07-18 |
Abbvie Inc |
inibidores de quinase cdk9
|
MX2015012432A
(es)
|
2013-03-13 |
2016-02-05 |
Abbvie Inc |
Inhibidores piridinicos de la cinasa cdk9.
|
AU2014231567A1
(en)
|
2013-03-14 |
2015-10-01 |
Abbvie Inc. |
Pyrrolo[2,3-b]pyridine CDK9 kinase inhibitors
|
AU2014244194A1
(en)
*
|
2013-03-14 |
2015-09-10 |
Abbvie Inc. |
Pyrrolopyrimindine CDK9 kinase inhibitors
|
TW201444836A
(zh)
|
2013-03-14 |
2014-12-01 |
Abbvie Inc |
吡咯并[2,3-b]吡啶cdk9激酶抑制劑
|
CN105473140B
(zh)
*
|
2013-03-15 |
2018-04-10 |
G1治疗公司 |
在化学疗法期间对正常细胞的瞬时保护
|
WO2014144596A2
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
SI2976106T1
(sl)
|
2013-03-21 |
2021-08-31 |
Array Biopharma Inc. |
Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec
|
WO2014172479A1
(en)
|
2013-04-16 |
2014-10-23 |
Memorial Sloan-Kettering Cancer Center |
Companion diagnostic for cdk4 inhibitors
|
DK3033086T3
(da)
*
|
2013-08-14 |
2022-01-03 |
Novartis Ag |
Kombinationsterapi til behandling af cancer
|
ES2674361T3
(es)
*
|
2013-08-28 |
2018-06-29 |
Novartis Ag |
Combinación de un inhibidor de ALK y un inhibidor de CDK para el tratamiento de enfermedades celulares proliferativas
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015049325A1
(en)
*
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
US20160257688A1
(en)
*
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
RU2016125133A
(ru)
|
2013-11-27 |
2018-01-09 |
Новартис Аг |
Комбинированная терапия, включающая применение ингибиторов jak, cdk и pim
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
US11013743B2
(en)
*
|
2013-12-20 |
2021-05-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
KR102283895B1
(ko)
*
|
2013-12-23 |
2021-07-30 |
노파르티스 아게 |
제약 조합물
|
JP6532878B2
(ja)
*
|
2013-12-23 |
2019-06-19 |
ノバルティス アーゲー |
組合せ医薬
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
CA2935103C
(en)
*
|
2013-12-31 |
2018-08-28 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN113583129A
(zh)
|
2014-03-14 |
2021-11-02 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
JP6783224B2
(ja)
|
2014-04-04 |
2020-11-11 |
デル マー ファーマシューティカルズ |
肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
|
WO2015160986A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
WO2015180642A1
(en)
*
|
2014-05-28 |
2015-12-03 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain protein kinase inhibitors
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
WO2016040892A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CN107001478B
(zh)
|
2014-10-14 |
2022-01-11 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
AU2015333689A1
(en)
|
2014-10-14 |
2017-05-25 |
The Regents Of The University Of California |
Use of CDK9 and BRD4 inhibitors to inhibit inflammation
|
ES2941897T3
(es)
|
2014-11-12 |
2023-05-26 |
Seagen Inc |
Compuestos que interaccionan con glicanos y procedimientos de uso
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
WO2016091221A1
(zh)
*
|
2014-12-12 |
2016-06-16 |
苏州晶云药物科技有限公司 |
吡咯并[2,3-d]嘧啶化合物的盐及盐的新晶型
|
US20160220569A1
(en)
*
|
2015-02-03 |
2016-08-04 |
G1 Therapeutics, Inc. |
CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
|
BR112017018908A2
(pt)
|
2015-03-10 |
2018-04-17 |
Aduro Biotech, Inc. |
composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
|
WO2016151501A1
(en)
|
2015-03-25 |
2016-09-29 |
Novartis Ag |
Pharmaceutical combinations
|
AU2016248017A1
(en)
|
2015-04-16 |
2017-10-19 |
Novartis Ag |
Ribociclib tablet
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
ES2893478T3
(es)
|
2015-05-29 |
2022-02-09 |
Teijin Pharma Ltd |
Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable del mismo
|
CN105037236B
(zh)
*
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
EP3340990B1
(en)
|
2015-08-28 |
2019-09-25 |
Novartis AG |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
CN108348513A
(zh)
|
2015-08-28 |
2018-07-31 |
诺华股份有限公司 |
用于治疗或预防癌症的ribociclib与达拉菲尼的组合
|
CN108135905A
(zh)
|
2015-08-28 |
2018-06-08 |
诺华股份有限公司 |
用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合
|
US10328066B2
(en)
|
2015-08-28 |
2019-06-25 |
Novartis Ag |
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
JP2018532750A
(ja)
|
2015-11-02 |
2018-11-08 |
ノバルティス アーゲー |
ホスファチジルイノシトール3−キナーゼ阻害剤の投薬レジメン
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
JP7066613B2
(ja)
|
2015-11-12 |
2022-05-13 |
シージェン インコーポレイテッド |
グリカン相互作用化合物および使用方法
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
WO2017162215A1
(zh)
*
|
2016-03-25 |
2017-09-28 |
正大天晴药业集团股份有限公司 |
取代的吡咯并嘧啶类cdk抑制剂、包含其的药物组合物以及它们的用途
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
CA3018434A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
TWI752026B
(zh)
|
2016-05-07 |
2022-01-11 |
大陸商上海複尚慧創醫藥研究有限公司 |
一類蛋白激酶抑制劑
|
CN108290899B
(zh)
*
|
2016-06-06 |
2020-09-18 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
PL3464272T3
(pl)
|
2016-06-07 |
2022-03-28 |
Jacobio Pharmaceuticals Co., Ltd. |
Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
CA3028751A1
(en)
*
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
KR102445288B1
(ko)
|
2016-07-01 |
2022-09-19 |
쥐원 쎄라퓨틱스, 인크. |
N-(헤테로아릴)-피롤로[3,2-d]피리미딘-2-아민의 합성
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
WO2018039324A1
(en)
|
2016-08-23 |
2018-03-01 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of hepatocellular carcinoma
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
RU2019111887A
(ru)
|
2016-10-20 |
2020-11-20 |
Пфайзер Инк. |
Антипролиферативные средства для лечения лаг
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
US11865176B2
(en)
|
2016-11-08 |
2024-01-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
EP3541391A4
(en)
*
|
2016-11-17 |
2020-06-17 |
The University of North Carolina at Chapel Hill |
ALKYL-PYRROLOPYRIMIDINE ANALOG AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
PT3546456T
(pt)
|
2016-11-28 |
2022-02-28 |
Teijin Pharma Ltd |
Cristal de derivado da pirido[3,4-d]pirimidina ou seu solvato
|
PL3546458T3
(pl)
|
2016-11-28 |
2021-06-14 |
Teijin Pharma Limited |
((pirydyn-2-ylo)amino)pirydo[3,4-d]pirymidynowe i ((pirydazyn-3-ylo)amino)pirydo[3,4-d]pirymidynowe pochodne jako inhibitory cdk4/6 w leczeniu np. reumatoidalnego zapalenia stawów, miażdżycy tętnic, zwłóknienia płuc, zawału mózgu lub raka
|
KR20240023677A
(ko)
|
2016-12-05 |
2024-02-22 |
쥐원 쎄라퓨틱스, 인크. |
화학요법 레지멘 동안의 면역 반응의 보존
|
JP7229162B2
(ja)
|
2017-01-06 |
2023-02-27 |
ジー1 セラピューティクス, インコーポレイテッド |
癌の治療に対する併用療法
|
WO2018140730A1
(en)
*
|
2017-01-27 |
2018-08-02 |
Signalrx Pharmaceuticals, Inc. |
Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
SG11201907889YA
(en)
|
2017-03-03 |
2019-09-27 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use
|
RU2764724C2
(ru)
|
2017-03-16 |
2022-01-19 |
ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. |
Комбинированная терапия для лечения рака молочной железы
|
EA202190196A1
(ru)
|
2017-03-23 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
TW201906818A
(zh)
|
2017-05-31 |
2019-02-16 |
美商511製藥公司 |
新穎氘取代之正子發射斷層掃描(pet)顯影劑及其藥理應用
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
EA201992768A1
(ru)
|
2017-06-29 |
2020-05-19 |
Г1 Терапьютикс, Инк. |
Морфологические формы g1t38 и способы их получения
|
WO2019026006A1
(en)
|
2017-08-03 |
2019-02-07 |
Novartis Ag |
THERAPEUTIC ASSOCIATION OF THIRD GENERATION EGFR TYROSINE KINASE INHIBITOR AND CYCLIN D KINASE INHIBITOR
|
EP3672968B1
(en)
|
2017-08-25 |
2023-11-01 |
Assia Chemical Industries Ltd |
Solid state form of ribociclib succinate
|
EP3676404A1
(en)
|
2017-08-31 |
2020-07-08 |
Novartis AG |
Methods of selecting a treatment for cancer patients
|
US11286259B2
(en)
|
2017-09-29 |
2022-03-29 |
Hangzhou Solipharma Co., Ltd. |
Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
|
EP3700908A1
(en)
|
2017-10-27 |
2020-09-02 |
Fresenius Kabi Oncology Ltd |
An improved process for the preparation of ribociclib and its salts
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
US11179365B2
(en)
|
2017-11-16 |
2021-11-23 |
Novartis Ag |
Pharmaceutical combination comprising LSZ102 and ribociclib
|
IL275490B1
(en)
*
|
2017-12-22 |
2024-01-01 |
Ravenna Pharmaceuticals Inc |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
WO2019123364A1
(en)
|
2017-12-22 |
2019-06-27 |
Shilpa Medicare Limited |
Novel polymorphs of ribociclib mono succinate
|
US10519136B2
(en)
*
|
2017-12-29 |
2019-12-31 |
Accutar Biotechnology |
Dual inhibitors of PARP1 and CDK
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
EP3738084A4
(en)
|
2018-01-08 |
2021-11-17 |
G1 Therapeutics, Inc. |
G1T38 SUPERIOR DOSAGE RATES
|
MX2020007959A
(es)
*
|
2018-01-29 |
2020-09-18 |
Beta Pharma Inc |
Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos.
|
SG11202007754UA
(en)
|
2018-02-15 |
2020-09-29 |
Nuvation Bio Inc |
Heterocyclic compounds as kinase inhibitors
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
CA3043066A1
(en)
|
2018-05-14 |
2019-11-14 |
Apotex Inc. |
Processes for the preparation of ribociclib and intermediates thereof
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
KR20210049847A
(ko)
|
2018-08-24 |
2021-05-06 |
쥐원 쎄라퓨틱스, 인크. |
1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
|
AU2019338032A1
(en)
*
|
2018-09-13 |
2021-05-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of substituted pyrrolopyrimidine CDK inhibitor, crystal and use thereof
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
CN113227089A
(zh)
|
2018-10-31 |
2021-08-06 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
US20230065740A1
(en)
*
|
2018-12-28 |
2023-03-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
WO2020140052A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
JP2022517842A
(ja)
|
2019-01-23 |
2022-03-10 |
ノバルティス アーゲー |
7-シクロペンチル-2-(5-ピペラジン-1-イル-ピリジン-2-イルアミノ)-7H-ピロロ[2,3-d]ピリミジン-6-カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態
|
CN113382731A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和瑞博西尼的药物组合
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2021009763A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
AR122270A1
(es)
|
2019-05-20 |
2022-08-31 |
Novartis Ag |
Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
EP3980411A1
(en)
*
|
2019-06-04 |
2022-04-13 |
Step Pharma S.A.S. |
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
EP4054583A4
(en)
*
|
2019-11-07 |
2023-10-25 |
Crinetics Pharmaceuticals, Inc. |
MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES
|
IL293940A
(en)
*
|
2019-12-16 |
2022-08-01 |
Lunella Biotech Inc |
Selective cancer drugs cdk4/6 inhibitors
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
CA3161892A1
(en)
|
2019-12-23 |
2021-07-01 |
Jie Fan |
Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
|
JP2023518508A
(ja)
*
|
2020-03-27 |
2023-05-01 |
江蘇康寧杰瑞生物制薬有限公司 |
腫瘍を治療するための抗her2抗体とcdk阻害剤の組み合わせ
|
US20230192703A1
(en)
*
|
2020-05-12 |
2023-06-22 |
Suzhou Alphama Biotechnology Co., Ltd. |
Polycyclic amide derivative as CDK9 inhibitor, preparation method therefor and use thereof
|
EP4149472A1
(en)
|
2020-05-12 |
2023-03-22 |
Novartis AG |
Therapeutic combinations comprising a craf inhibitor
|
US20230219961A1
(en)
*
|
2020-05-12 |
2023-07-13 |
Suzhou Alphama Biotechnology Co., Ltd. |
Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
|
KR20230012547A
(ko)
|
2020-05-19 |
2023-01-26 |
쥐원 쎄라퓨틱스, 인크. |
의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
WO2022112942A2
(en)
|
2020-11-24 |
2022-06-02 |
Novartis Ag |
Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
|
JP2023553808A
(ja)
|
2020-11-24 |
2023-12-26 |
ノバルティス アーゲー |
Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
AU2022218128A1
(en)
|
2021-02-02 |
2023-08-17 |
Les Laboratoires Servier |
Selective bcl-xl protac compounds and methods of use
|
EP4313987A2
(en)
|
2021-04-01 |
2024-02-07 |
KRKA, d.d., Novo mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
WO2022234409A1
(en)
|
2021-05-05 |
2022-11-10 |
Novartis Ag |
Compounds and compositions for the treatment of mpnst
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
IL310243A
(en)
|
2021-07-26 |
2024-03-01 |
Celcuity Inc |
1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORHOLIN-4-YL-1,3,5-TRIAZIN-2-YL )PHENYL]urea (GEDATOLISIB) and its combinations for use in cancer treatment
|
KR20240041340A
(ko)
*
|
2021-07-27 |
2024-03-29 |
보로노이 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
TW202329977A
(zh)
|
2022-01-25 |
2023-08-01 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
WO2023196517A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
WO2023196518A1
(en)
*
|
2022-04-08 |
2023-10-12 |
Biolexis Therapeutics, Inc. |
Cdk9 inhibitors
|
WO2023225336A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2024049926A1
(en)
|
2022-08-31 |
2024-03-07 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|